Originally published as JCO Early Release 10.1200/JCO.2005.10.021 on May 23 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Long, H. J. Articles by Fiorica, J. V. Search for Related Content PubMed PubMed Citation Articles by Long, H. J., III Articles by Fiorica, J. V. Social Bookmarking                            What's this?

Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study

From the Mayo Clinic College of Medicine, Rochester, MN; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Gynecologic Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL; Departments of Pathology, and Obstetrics and Gynecology, University of Iowa Hospitals and Clinics; University of Iowa Hospitals, Division of Gynecologic Oncology, Iowa City, IA; Fellowship Program in Gynecologic Oncology, University of Oklahoma, Health Sciences Center, Oklahoma City, OK; Dallas Foundation Chair in Gynecologic Oncology, University of Texas Southwestern Medical Center at Dallas, Division of Gynecologic Oncology, Dallas, TX; Division of Gynecologic Oncology, Ohio State University College of Medicine, and James Cancer Hospital and Solove Research Institute, Columbus, OH; Gynecologic Oncology Program, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL

Address reprint requests to Denise Mackey, GOG Administrative Office, Four Penn Center, Suite 1020, 1600 John F. Kennedy Blvd, Philadelphia, PA 19103; e-mail: dmackey{at}gog.org

PURPOSE: On the basis of reported activity of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) or topotecan plus cisplatin in advanced cervix cancer, we undertook a randomized trial comparing these combinations versus cisplatin alone, to determine whether survival is improved with either combination compared with cisplatin alone, and to compare toxicities and quality of life (QOL) among the regimens.

PATIENTS AND METHODS: Eligible patients were randomly allocated to receive cisplatin 50 mg/m² every 3 weeks (CPT); cisplatin 50 mg/m² day 1 plus topotecan 0.75 mg/m² days 1 to 3 every 3 weeks (CT); or methotrexate 30 mg/m² days 1, 15, and 22, vinblastine 3 mg/m² days 2, 15, and 22, doxorubicin 30 mg/m² day 2, and cisplatin 70 mg/m² day 2 every 4 weeks (MVAC). Survival was the primary end point; response rate and progression-free survival (PFS) were secondary end points. QOL data are reported separately.

RESULTS: The MVAC arm was closed by the Data Safety Monitoring Board after four treatment-related deaths occurred among 63 patients, and is not included in this analysis. Two hundred ninety-four patients enrolled onto the remaining regimens: 146 to CPT and 147 to CT. Grade 3 to 4 hematologic toxicity was more common with CT. Patients receiving CT had statistically superior outcomes to those receiving CPT, with median overall survival of 9.4 and 6.5 months (P = .017), median PFS of 4.6 and 2.9 months (P = .014), and response rates of 27% and 13%, respectively.

CONCLUSION: This is the first randomized phase III trial to demonstrate a survival advantage for combination chemotherapy over cisplatin alone in advanced cervix cancer.

Supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office (CA 27469) and the GOG Statistical and Data Center (CA 37517).

Presented in abstract form at the Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, February 8, 2004.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I. Saito, R. Kitagawa, H. Fukuda, T. Shibata, N. Katsumata, I. Konishi, H. Yoshikawa, and T. Kamura A Phase III Trial of Paclitaxel plus Carboplatin Versus Paclitaxel plus Cisplatin in Stage IVB, Persistent or Recurrent Cervical Cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505) Jpn. J. Clin. Oncol., October 12, 2009; (2009) hyp117v1. [Abstract] [Full Text] [PDF]

				B. J. Monk, M. W. Sill, D. S. McMeekin, D. E. Cohn, L. M. Ramondetta, C. H. Boardman, J. Benda, and D. Cella Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study J. Clin. Oncol., October 1, 2009; 27(28): 4649 - 4655. [Abstract] [Full Text] [PDF]

				G. Mountzios, M. A. Dimopoulos, A. Bamias, G. Vourli, H. Kalofonos, G. Aravantinos, G. Fountzilas, and C. A. Papadimitriou Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study Ann. Onc., August 1, 2009; 20(8): 1362 - 1368. [Abstract] [Full Text] [PDF]

				D. Lorusso, G. Ferrandina, S. Pignata, M. Ludovisi, R. Vigano, S. Scalone, P. Scollo, E. Breda, A. Pietragalla, and G. Scambia Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group Ann. Onc., July 15, 2009; (2009) mdp266v1. [Abstract] [Full Text] [PDF]

				D. S. Boss, W. S. Siegel-Lakhai, N. E. van Egmond-Schoemaker, D. Pluim, H. Rosing, W. W. ten Bokkel Huinink, J. H. Beijnen, and J. H.M. Schellens Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors Clin. Cancer Res., July 1, 2009; 15(13): 4475 - 4483. [Abstract] [Full Text] [PDF]

				K. Lang, M. Sussman, M. Friedman, J. Su, H. J. Kan, D. Mauro, E. Tafesse, and J. Menzin Incidence and Costs of Treatment-Related Complications Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Arch Otolaryngol Head Neck Surg, June 1, 2009; 135(6): 582 - 588. [Abstract] [Full Text] [PDF]

				B. J. Monk, M. W. Sill, R. A. Burger, H. J. Gray, T. E. Buekers, and L. D. Roman Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study J. Clin. Oncol., March 1, 2009; 27(7): 1069 - 1074. [Abstract] [Full Text] [PDF]

				S. Movva, M. Gold, P. Grigsby, and C. Verschraegen Challenges in the Management of Invasive Cervical Cancer ASCO Educational Book, January 1, 2009; 2009(1): 295 - 300. [Abstract] [Full Text] [PDF]

				H. J. Long III, N. N. I. Laack, and B. S. Gostout Prevention, Diagnosis, and Treatment of Cervical Cancer Mayo Clin. Proc., December 1, 2007; 82(12): 1566 - 1574. [Abstract] [Full Text] [PDF]

				S. A. Cannistra and W. P. McGuire Progress in the Management of Gynecologic Cancer J. Clin. Oncol., July 10, 2007; 25(20): 2865 - 2866. [Full Text] [PDF]

				H. J. Long III Management of Metastatic Cervical Cancer: Review of the Literature J. Clin. Oncol., July 10, 2007; 25(20): 2966 - 2974. [Abstract] [Full Text] [PDF]

				S. A. Cannistra Gynecologic Oncology or Medical Oncology: What's in a Name? J. Clin. Oncol., April 1, 2007; 25(10): 1157 - 1159. [Full Text] [PDF]

				I. van Luijk, C Coens, M. van der Burg, A Kobierska, M Namer, C Lhomme, P Zola, G Zanetta, J. Vermorken, and For the Gynecological Cancer Group of the European Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix Ann. Onc., February 1, 2007; 18(2): 275 - 281. [Abstract] [Full Text] [PDF]